These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
687 related articles for article (PubMed ID: 31409745)
1. An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies. Cao J; Chen L; Li H; Chen H; Yao J; Mu S; Liu W; Zhang P; Cheng Y; Liu B; Hu Z; Chen D; Kang H; Hu J; Wang A; Wang W; Yao M; Chrin G; Wang X; Zhao W; Li L; Xu L; Guo W; Jia J; Chen J; Wang K; Li G; Shi W Oncologist; 2019 Dec; 24(12):e1294-e1302. PubMed ID: 31409745 [TBL] [Abstract][Full Text] [Related]
2. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer. Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687 [TBL] [Abstract][Full Text] [Related]
3. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study. Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081 [TBL] [Abstract][Full Text] [Related]
4. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. Vanderwalde A; Spetzler D; Xiao N; Gatalica Z; Marshall J Cancer Med; 2018 Mar; 7(3):746-756. PubMed ID: 29436178 [TBL] [Abstract][Full Text] [Related]
5. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702 [TBL] [Abstract][Full Text] [Related]
6. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255 [TBL] [Abstract][Full Text] [Related]
7. Mutation Burden and I Index for Detection of Microsatellite Instability in Colorectal Cancer by Targeted Next-Generation Sequencing. Kim JE; Chun SM; Hong YS; Kim KP; Kim SY; Kim J; Sung CO; Cho EJ; Kim TW; Jang SJ J Mol Diagn; 2019 Mar; 21(2):241-250. PubMed ID: 30389464 [TBL] [Abstract][Full Text] [Related]
8. Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy. Goodman AM; Sokol ES; Frampton GM; Lippman SM; Kurzrock R Cancer Immunol Res; 2019 Oct; 7(10):1570-1573. PubMed ID: 31405947 [TBL] [Abstract][Full Text] [Related]
9. A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors. Conroy JM; Pabla S; Glenn ST; Seager RJ; Van Roey E; Gao S; Burgher B; Andreas J; Giamo V; Mallon M; Lee YH; DePietro P; Nesline M; Wang Y; Lenzo FL; Klein R; Zhang S PLoS One; 2021; 16(12):e0260089. PubMed ID: 34855780 [TBL] [Abstract][Full Text] [Related]
10. Clinical and Technical Validation of OncoIndx Ramesh A; Bharde A; D'Souza A; Jadhav B; Prajapati S; Hariramani K; Basavalingegowda M; Iyer S; Halder S; Deochake M; Kothavade H; Vasudevan A; Uttarwar M; Khandare J; Shafi G Cancers (Basel); 2024 Oct; 16(19):. PubMed ID: 39410034 [TBL] [Abstract][Full Text] [Related]
11. Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing. Al Zoughbi W; Fox J; Beg S; Papp E; Hissong E; Ohara K; Keefer L; Sigouros M; Kane T; Bockelman D; Nichol D; Patchell E; Bareja R; Karandikar A; Alnajar H; Cerqueira G; Guthrie VB; Verner E; Manohar J; Greco N; Wilkes D; Tagawa S; Malbari MS; Holcomb K; Eng KW; Shah M; Altorki NK; Sboner A; Nanus D; Faltas B; Sternberg CN; Simmons J; Houvras Y; Molina AM; Angiuoli S; Elemento O; Mosquera JM Oncologist; 2021 Nov; 26(11):e1971-e1981. PubMed ID: 34286887 [TBL] [Abstract][Full Text] [Related]
12. Validation of a Targeted Next-Generation Sequencing Panel for Tumor Mutation Burden Analysis: Results from the Onconetwork Immuno-Oncology Consortium. Fenizia F; Alborelli I; Costa JL; Vollbrecht C; Bellosillo B; Dinjens W; Endris V; Heydt C; Leonards K; Merkelback-Bruse S; Pfarr N; van Marion R; Allen C; Chaudhary R; Gottimukkala R; Hyland F; Wong-Ho E; Jermann P; Machado JC; Hummel M; Stenzinger A; Normanno N J Mol Diagn; 2021 Jul; 23(7):882-893. PubMed ID: 33964449 [TBL] [Abstract][Full Text] [Related]
13. A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability-High Cases in 67,000 Patient Samples. Trabucco SE; Gowen K; Maund SL; Sanford E; Fabrizio DA; Hall MJ; Yakirevich E; Gregg JP; Stephens PJ; Frampton GM; Hegde PS; Miller VA; Ross JS; Hartmaier RJ; Huang SA; Sun JX J Mol Diagn; 2019 Nov; 21(6):1053-1066. PubMed ID: 31445211 [TBL] [Abstract][Full Text] [Related]
15. Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material. Steeghs EMP; Kroeze LI; Tops BBJ; van Kempen LC; Ter Elst A; Kastner-van Raaij AWM; Hendriks-Cornelissen SJB; Hermsen MJW; Jansen EAM; Nederlof PM; Schuuring E; Ligtenberg MJL; Eijkelenboom A BMC Cancer; 2020 Apr; 20(1):291. PubMed ID: 32264863 [TBL] [Abstract][Full Text] [Related]
16. Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer. Park S; Lee C; Ku BM; Kim M; Park WY; Kim NKD; Ahn MJ BMB Rep; 2021 Jul; 54(7):386-391. PubMed ID: 34154699 [TBL] [Abstract][Full Text] [Related]
17. Distinct mutational profile and immune microenvironment in microsatellite-unstable and Hwang HS; Kim D; Choi J J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34607897 [TBL] [Abstract][Full Text] [Related]
18. Microsatellite instability status is determined by targeted sequencing with MSIcall in 25 cancer types. Hirotsu Y; Nagakubo Y; Amemiya K; Oyama T; Mochizuki H; Omata M Clin Chim Acta; 2020 Mar; 502():207-213. PubMed ID: 31730810 [TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer. Zang YS; Dai C; Xu X; Cai X; Wang G; Wei J; Wu A; Sun W; Jiao S; Xu Q Cancer Med; 2019 Aug; 8(10):4699-4708. PubMed ID: 31270941 [TBL] [Abstract][Full Text] [Related]
20. Concordance Study of a 520-Gene Next-Generation Sequencing-Based Genomic Profiling Assay of Tissue and Plasma Samples. Wang M; Chen X; Dai Y; Wu D; Liu F; Yang Z; Song B; Xie L; Yang L; Zhao W; Zhang C; Shen W; Fan C; Teng C; Zhao X; Gao N; Shang D; Zhao G; Xin T Mol Diagn Ther; 2022 May; 26(3):309-322. PubMed ID: 35305253 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]